Senseonics Holdings, Inc. (NASDAQ: SENS) increased the maximum borrowing capacity of its loan and security agreement with Hercules Capital, Inc. from $100 million to $140 million. The amendment, finalized on May 4 2026, also confirmed that $35 million of the original facility remains outstanding, bringing total debt under the agreement to roughly $55 million after the first $10 million tranche is funded at closing and a second $10 million tranche is expected to close on May 6.
With $64.6 million in cash and cash equivalents as of March 31 2026 and proceeds from an $80 million public equity offering priced on May 1 2026 and closing on May 4, Senseonics now has a combined liquidity position that should support operations through 2028. The expanded credit line provides additional flexibility to fund the commercial rollout of the Eversense 365 implantable continuous glucose monitor, pursue pipeline development, and meet working‑capital needs as the company transitions to a direct‑to‑consumer model that began in the U.S. on January 1 2026 after taking over commercialization from Ascensia Diabetes Care.
The move directly addresses the liquidity risk highlighted in the company’s Q4 2025 earnings report, which warned of potential covenant breaches in the third quarter of 2026. By increasing borrowing capacity, Senseonics mitigates the risk of a liquidity crunch and preserves momentum in its commercial expansion and product development plans. The additional capital also supports the company’s strategy to scale the Eversense 365, which has seen strong demand in new markets such as Sweden and is slated for expansion into Germany, Spain, and Italy.
Prior financials illustrate the context for the liquidity upgrade: Q4 2025 revenue was $14.3 million, a 72 % year‑over‑year increase, but the company posted a net loss of $20.8 million. Preliminary Q1 2026 figures show revenue of approximately $11.7 million and a net loss between $31 million and $33 million, underscoring the need for additional working‑capital support. The credit facility expansion, combined with the equity raise, provides a buffer that extends the company’s runway to 2028 and reduces the likelihood of covenant violations.
CFO Rick Sullivan emphasized the importance of the expanded relationship with Hercules Capital in supporting commercial operations and pipeline development. The enhanced credit line, together with the equity proceeds, positions Senseonics to accelerate its direct‑to‑consumer strategy and sustain growth in the competitive continuous glucose monitoring market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.